TW293008B - - Google Patents
Download PDFInfo
- Publication number
- TW293008B TW293008B TW083100912A TW83100912A TW293008B TW 293008 B TW293008 B TW 293008B TW 083100912 A TW083100912 A TW 083100912A TW 83100912 A TW83100912 A TW 83100912A TW 293008 B TW293008 B TW 293008B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- patent application
- pyridine
- scope
- item
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 102
- VNHBYKHXBCYPBJ-UHFFFAOYSA-N 5-ethynylimidazo[1,2-a]pyridine Chemical compound C#CC1=CC=CC2=NC=CN12 VNHBYKHXBCYPBJ-UHFFFAOYSA-N 0.000 claims description 28
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 25
- -1 2-methoxycarbonylamino-6-methylbenzylamino Chemical group 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 21
- 238000011049 filling Methods 0.000 claims description 15
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 239000007789 gas Substances 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 150000004678 hydrides Chemical class 0.000 claims description 2
- 208000028774 intestinal disease Diseases 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 239000012442 inert solvent Substances 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 235000015067 sauces Nutrition 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 35
- 239000002253 acid Substances 0.000 description 21
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 17
- 239000000203 mixture Substances 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 15
- 239000002904 solvent Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000013543 active substance Substances 0.000 description 10
- 229910052786 argon Inorganic materials 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000009858 acid secretion Effects 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 208000004350 Strabismus Diseases 0.000 description 5
- 235000013405 beer Nutrition 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 235000009518 sodium iodide Nutrition 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 150000002828 nitro derivatives Chemical class 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 3
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- XMPZLAQHPIBDSO-UHFFFAOYSA-N argon dimer Chemical compound [Ar].[Ar] XMPZLAQHPIBDSO-UHFFFAOYSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000002079 cooperative effect Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- UCEMDZZFZIWBPW-UHFFFAOYSA-N methyl n-[2-(bromomethyl)-3-methylphenyl]carbamate Chemical compound COC(=O)NC1=CC=CC(C)=C1CBr UCEMDZZFZIWBPW-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 2
- 229910001948 sodium oxide Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 2
- 229960002372 tetracaine Drugs 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GIWQSPITLQVMSG-UHFFFAOYSA-N 1,2-dimethylimidazole Chemical compound CC1=NC=CN1C GIWQSPITLQVMSG-UHFFFAOYSA-N 0.000 description 1
- VSWPGAIWKHPTKX-UHFFFAOYSA-N 1-methyl-10-[2-(4-methyl-1-piperazinyl)-1-oxoethyl]-5H-thieno[3,4-b][1,5]benzodiazepin-4-one Chemical compound C1CN(C)CCN1CC(=O)N1C2=CC=CC=C2NC(=O)C2=CSC(C)=C21 VSWPGAIWKHPTKX-UHFFFAOYSA-N 0.000 description 1
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
- BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- OOKDYUQHMDBHMB-UHFFFAOYSA-N 3,6-dichloro-2-methoxybenzoic acid;2-(2,4-dichlorophenoxy)acetic acid;n-methylmethanamine Chemical compound CNC.CNC.COC1=C(Cl)C=CC(Cl)=C1C(O)=O.OC(=O)COC1=CC=C(Cl)C=C1Cl OOKDYUQHMDBHMB-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- GGZZISOUXJHYOY-UHFFFAOYSA-N 8-amino-4-hydroxynaphthalene-2-sulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C2C(N)=CC=CC2=C1O GGZZISOUXJHYOY-UHFFFAOYSA-N 0.000 description 1
- 240000000073 Achillea millefolium Species 0.000 description 1
- 235000007754 Achillea millefolium Nutrition 0.000 description 1
- 229910052695 Americium Inorganic materials 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- SHDMUTAPDHJSDO-UHFFFAOYSA-J C([O-])(O)=O.[Na+].[B+3].C([O-])(O)=O.C([O-])(O)=O.C([O-])(O)=O Chemical compound C([O-])(O)=O.[Na+].[B+3].C([O-])(O)=O.C([O-])(O)=O.C([O-])(O)=O SHDMUTAPDHJSDO-UHFFFAOYSA-J 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- 229910052691 Erbium Inorganic materials 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 241000282346 Meles meles Species 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- DUDKAZCAISNGQN-UHFFFAOYSA-N Oxyphencyclimine Chemical compound CN1CCCN=C1COC(=O)C(O)(C=1C=CC=CC=1)C1CCCCC1 DUDKAZCAISNGQN-UHFFFAOYSA-N 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- DYQVUHJGPRMPQI-UHFFFAOYSA-N Pulic acid Natural products CC1CCC(=C)C(=C/C=CCC1(C)CCC2=CC(O)OC2=O)C(=O)O DYQVUHJGPRMPQI-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- WJEIYVAPNMUNIU-UHFFFAOYSA-N [Na].OC(O)=O Chemical compound [Na].OC(O)=O WJEIYVAPNMUNIU-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- AYAJGJDDWNWXDL-UHFFFAOYSA-N acetic acid;carbonocyanidic acid Chemical compound CC(O)=O.OC(=O)C#N AYAJGJDDWNWXDL-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- HJCUTNIGJHJGCF-UHFFFAOYSA-N acridan acid Natural products C1=CC=C2CC3=CC=CC=C3NC2=C1 HJCUTNIGJHJGCF-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- LXQXZNRPTYVCNG-UHFFFAOYSA-N americium atom Chemical compound [Am] LXQXZNRPTYVCNG-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001262 anti-secretory effect Effects 0.000 description 1
- 230000002181 anti-sympathetic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- CMBZEFASPGWDEN-UHFFFAOYSA-N argon;hydrate Chemical class O.[Ar] CMBZEFASPGWDEN-UHFFFAOYSA-N 0.000 description 1
- HRDJIMDVNVUCFH-UHFFFAOYSA-N argon;oxolane Chemical compound [Ar].C1CCOC1 HRDJIMDVNVUCFH-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- LNWKGPUOGQZZAP-UHFFFAOYSA-N butyl n-[chloro-(2-methylphenyl)methyl]carbamate Chemical compound CCCCOC(=O)NC(Cl)C1=CC=CC=C1C LNWKGPUOGQZZAP-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000005323 carbonate salts Chemical class 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical compound O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052806 inorganic carbonate Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N methylimidazole Natural products CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229960002369 oxyphencyclimine Drugs 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229960005019 pantoprazole Drugs 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 238000002161 passivation Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000005554 pickling Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 1
- 229960004633 pirenzepine Drugs 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- IVRIRQXJSNCSPQ-UHFFFAOYSA-N propan-2-yl carbonochloridate Chemical compound CC(C)OC(Cl)=O IVRIRQXJSNCSPQ-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- BZGIPVGCJGXQTA-UHFFFAOYSA-N s-[2-(diethylamino)ethyl] n,n-diphenylcarbamothioate Chemical compound C=1C=CC=CC=1N(C(=O)SCCN(CC)CC)C1=CC=CC=C1 BZGIPVGCJGXQTA-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229950004351 telenzepine Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- XPDWGBQVDMORPB-UHFFFAOYSA-N trifluoromethane acid Natural products FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
233008 A6 _B6__ 五、發明説明(1 ) 發明醏_ : 本發明係Μ於意圓利用於《藥工業當做活性物質*以製 造Β藥之新穎咪唑吡啶。 S_EJS_i_: 歐洲專利申誚案ΕΡ-Α-0 033 094係說明咪唑[1,2-a]% 啶,其於第8位置具有一儷芳基取代基,較佳者係一髑苯 基,嚐嗯基或烴氯,氟,甲基•三级丁基•三氟甲基•甲 氣基或氰基取代之吡啶基或笨基。於ΕΡ-Α-0 033 094所提 及之較佳芳基係苯基*鄰或對氟苯基,對氯苯基及 ' 2,4,6 -三甲基苯基•於此類苯基中,最佳者係鄰或對氟苯 基及2,4,6 -三甲基苯基。歐洲專利申請案ΕΡ-Α-0 204 285, ΕΡ-Α-0 228 006, ΕΡ-Α-0 268 989及 ΕΡ-Α-0 308 917係說明咪唑[1,2-a]吡啶,其於第3位置具有一腼不胞 和脂肪基,特別係一個(經取代)炔基。歃洲専利申謫案 ΕΡ-Α-0 226 890係說明咪唑[1,2-a]吡啶,其於第8位置 經一僩烯基,烷基或環烷基烷基取代。 洚細說明: 經濟部中央搮準局貝工消费合作社印製 (請先《讀背面之注意事項再媾寫本頁) 已發現,將於下文說明,且不同於先前技蕕化合物之化 合物,特別係於第3或8位置被取代者,具有令人訝異及非 常有利之性霣。 本發明係鼷於通式I之化合物(參閲附錄之化學式), 其中 β 本紙張尺度遑用Ί»鼸鼴家樣準(CNS)甲4规格(210X297公釐) A6 B6 經濟部t央樣準局員工消费合作杜印製 五、發明説明(2 ) R0 表示甲基或羥甲基 R1 表示1-4C烷基 R2 表示1-4C烷基 R3 表示1-4C烷氧基 A 表示0 (氧)或NH 及其鹽類。 1-4C烷基代表具1一 4届碳原子之直鍵或支鐽烷基。實例 偽如丁基,異丁基•第二丁基.第三丁基,丙基•異丙基 *乙基及最佳之甲基。 卜4C烷氧基代表一個氧原子雄结至上述提及之卜4C焼基 。較佳者係甲氧基。 通式I化合物之逋畨蘧類最好係所有酸加成鹽類。特別 提及者可由習用於B藥技術之無櫬和有櫬Μ類之B蕖相容 性鹽類製成。翳蕖不相容之鹽類,例如,於工業規棋下, 用於製備根據本發明化合物方法之起始產物,可輻热練工 作人員之習知方法•將其轉換成Β藥相容之邇類。逋當之 類係水溶性或水不溶性酸加成鹽類與酸•例如氫氰酸,氫 溴酸,磷酸•礴酸•硫酸,醋酸,檸檬酸,D-葡糖酸,苯 甲酸· 2-(4-羥基苯甲豳)苯甲酸,丁酸,磺基水檯酸,順 式丁烯二酸,十二酸,羥基丁二酸,反式丁烯二酸,丁二 酸.,乙二酸,酒石酸,英邦酸(embonic acid) *十八酸, 甲苯磺酸•甲垸磺酸或3-羥基-2-菜甲酸,為製傅鹽類而 使用之酸類含量比例係等當量或根據此酸你單價或多價_ 性或依據所需鹽類而不同。 4 本紙張Λ度逋用t 鼸家樣準(CNS>甲4规格(210X 297公釐) 裝......................訂.....................線 {請先閱讀背面之注意事項再填窝本頁} A6 B6 經濟部申夹橒準局貝工消费合作社印製 五、發明説明(5 ) 可提及之較佳化合物實例係如下之化合物:3 -羥甲基 甲氧羰胺基-6-甲苄基胺基)-2-甲基咪唑[l,2-a]Pft ’ 3-羥甲基- 8-(2-甲氧羰胺基-6-甲苄基氧)_ 2-甲基咪 吡啶· 8-(2-甲氧羰胺基-6-甲苄基胺基)-2,3-二甲ϋ咪唑[1,2-a]吡啶及8-(2-甲氧锇胺基-6-甲苄基氧 二甲基咪唑[u-a]吡啶和其鹽類。 #發明進一步係Μ於一種製備通式I之化合物及其鹽類 之方法。此製法包含: 為了製備通式I之化合物•其中R0代表羥甲基,令通式 11之彳b合物堪原(參閲附錄之化學式>·其中R1.R2, R3及A具有上文提及之意義,或包含 b)為了製備通式I之化合物,其中R0代表甲基,令通式I t彳b合物(參閱附錄之化學式),其中R1及 A具有上文提 及之惠義,與通式IV之化合物(參閲附錄之化學式)反應 *其中R2及R3具有上文提及之意義,且)(代表一個適當之 離去*,或包含 c>為了製傅通式I之化合物,其中R〇代表甲綦,令通式V 之化合物(參閲附錄之化學式)·其中R1及R2具有上文提 及之意義,與通式VI之化合物(參閲附錄之化學式)反應 ’其中R3具有上文捉及之意義,且γ代表一個通當之蘼去 基, 且如果須要,雄而將所得之化合物I轉換成其鹽類〖或包 括,如果須要,接著自化合物I之所得蘧類釋放出化合物 本紙張尺度遴用肀國鷉家檫準(CNS)T4规格(210X297公釐) ..................................裝......................訂..................…線 <請先閲讀背面之注意事項再填寫本頁一 293008 A6 B6 經濟部中央棵準局貝工消费合作杜印製 五、發明説明(4 ) 化合物I之堪原係Μ热練工作人員热悉之一棰方式進行 。其係發生於如較低脂肪酵類之鈍化溶劑中,例如鞴利用 缠當之氫化物,如班S化納,如果須要,亦可加入水。 化合物1輿化合物IV之反應係Μ热練工作人員热悉之方 式進行,例如,賴 European Patent Applications ΕΡ-Α -0 033 094或ΕΡ-Α-0 308 917等相似文獻所說明之方法進 行。埋當之難去基係如一僩鹵素原子(較佳者係氯或溴) 或一儸甲烷磺釀氧基。該反應利於一種觭存在下進行(亦 即,一種無櫬氬氧化物,如S氧化納,或一種無機碳酸鹽 •如碳酸鉀,或一種有機氮驗,如三乙基胺,吡啶,可力 丁(collidin)或4 -二甲基胺基吡啶),其中反應之遇程可 藉肋於加入觸媒,如驗性碘化物或溴化四丁基銨。 化合物V與化合物VI之反應亦係以热練工作人員热悉之 方式進行,即如習於製備芳族氨基甲酸乙酷類.較佳者係 賴於鈍化溶.劑中,令化合物V與鹵素甲酸酯類(Y =鹵素) ’如氣甲酸酯類等反應。該反應利於一種酸黏合劑(質子 接受者)存在下進行。霣子接受者提及之*例係如《I金饜 礙酸鹽類(如碳酸鉀)或碳氫酸鹽類(如碳氫酸納)·或 三级胺類(如三乙基胺)。 热練之工作人員可由其専業知識而明瞭進行此方法所須 之特定反應條件。 根據本發明之物質偽依習知方法而分鐮及纯化*例如Μ —種方法,即於真空中*薄蒸皤而去除溶劑•所得之殘留 物以一種適當之溶劑或令其進行習用之純化方法,如於通 - 6 - 本紙張尺度遴用中國鼸家檫m(CNS)f4规格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁) .裝 訂 A6 B6 經濟部t夬標準局貝工消费合作杜印製 五、發明説明(5 ) 當載體材料上之層析分維法,而再结晶。 酸加成醴類之獲取係《將該自由鹼溶解於一棰適嘗溶劑 中•例如一種經氰化碳氬化物,如二氯甲烷或氯仿,或一 種較低之脂肪酵(乙酵*異丙酵)* 一種_,如丙釅•或 一棰81,如四S呋喃或二異丙基®,其中含有所須之酸或 繼而加入所須之酸。 該蘧類係薄過濾•再沉激·與一種用於該加成鹽之非溶 劑一起沉激或藉蒸發該溶01而分_。所得之類可«_(化 ♦例如以氛水溶液*而轉換成自由鐮類,換言之·其可轉 換成酸加成鹽類。其可以此種方法將B蕖不相容之酸加成 鼸類轉換成翳蕖相容之酸加成蘧類。 起始化合物I[可依一種習知方式製備•例如•令化合物 VI與化合物VBI (參閱附錄之化學式)反應,其中R1,R2· R3及A具有上文提及之意義,X係一個適當之離去基,例 如一個鹵素原子(較佳者涤氰或溴),或賴於European P a t e n t A p ί> 1 ί c a t i ο n s E P - A - 0 0 3 3 0 9 4 或 E P - A - 0 3 0 8 917等說明之相似懕用方法。 起始化合物 Μ 係由 European Patent Application ΕΡ-Α-0 299 47 0得知,起始化合物IV係由European Patent Application EP-A-0 308 917得知。 起始化合物V可由一種習知方法•自相f之硝基化合物 ,韉還原而得。該硝基化合物本身可由化合物I及與化合 物IV相當之通當硝基化合物製備。 提供下列實例係為詳细解釋根據本發明化合物之製備。 (請先閲讀背面之注意事項再填寫本頁} .装 .訂 .線 本紙張尺度遑用t··家榣準(CH8)甲4规格(210X297公釐) A6 B6 經濟部t央標準局w工消费合作社印製 五、發明説明(6 ) 持別地,該些實例係舉例說明根據製程赛數a· b及c之反 應和經選擇起始化合物之製備。相似地,未明確說明其製 儀之通式I之進一步化合物和進一步之起化合物,可以一 種相似之方法或以一棰热練工作人員热知之方法•賴平常 之製程技術而製備。縮寫RT代表室溫· h代表小時, ».P.代表溶黏· dec.代表分解。β_ffiL L 田》申氬糖防某-ft-田笮某瞄蠤田某眯 映Π . ? - a 1吡唯 於室溫下,將一種l〇n丨乾烯四氫呋喃中之400ng商業化 80!C氬化納懸浮液加人至於40ml乾嫌四氫呋喃中之2g 8-胺 基-3-甲鼸-2-甲基咪唑[1,2-a]吡啶溶液中。於50T短暫 加热,繼而激烈放出氣體。於氣體完全釋放後•冷卻該混 合物至0=·並逐滴加人一種於40 ml乾缲四氫呋喃中之 3.9g 2-甲氧羰胺基-6-甲苄基溴。再將該混合物加热至 50 υ,並保持於此溫度3h。然後將其倒入冰水中,Μ —些 稀》酸中和,並Κ醋酸乙酯萃取四次。以水清洗該經收集 之有櫬相,並於硫酸納之上乾缲。於真空中去除該溶劑, 並於氧化矽膠上(酷酸乙酯:石油醚=1:1為洗提液),將 該暗棕色黏稠殘留物曆析分離。自異丙酵中再结晶,獲得 2.5g 之檷题化合物,π.ρ. 188 — 190Ό (dec.)。 2 禪田蠤- -田藴羝肱某-fi -田竿某胺某)-9 -田其
(請先閲讀背面之注意事項再墣窝本頁I 裝 訂 .線 本紙»尺度遴用t 國家棵準(CNS1T4规格(210X297公*) 293008 經濟部中央櫟準局貝工消费合作社印製 A6 B6_ 五、發明説明(7 ) 眯啤f 1 . 丨Bf晾 於室溫下,令2s之3-甲醯-8-(2-甲氧捩胺*-6-甲苄基 胺基>-2-甲基咪唑[1,2-a]吡啶懸浮於30ml甲酵中•將 〇.2g之硼fi化納分成數部分加入,並於室溫下攪拌該混合 物lh。接著於興空中去除半數溶劑,將該殘留物到入冰水 中,Μ數滴稀鹽酸中和該混合物,並K酗酸乙酯萃取四次 。以水濟洗該經收集之有機相·並於硫酸納之上乾嫌。於 興空中去除該溶劑。剌餘之淡黄色残留物經一段時間後即 完全结晶。自黼酸乙酯中再结晶•獲得1.3g之禰Η化合物 • m . p . 170-172 t:- 3. 3-甲醣- «- (2 -甲氬錐肱某-fi -甲笮某氬-申某眯啤 「1 · 2-a 1 flf 晾 令2.6s之3-甲醚-8-羥基-2-甲基咪唑[1,2-a]吡啶溶解 於50m丨之丙烯•並於50 1C排除濕氣,络冷卻至室溫後•加 入於矽薄土 (例如Cel iteR)上之2. 8s商業化氣化鉀( 50»重量比)。逐滴加入一棰於5〇1«1乾煉丙烯騎中之3.68 2-甲氧羰胺基-6-甲苄基溴溶液•將該混合物加熱至70 1C * 6h.於冷卻至室溫後,將該混合物倒入冰水中,K數滴 6N氳氧化納調整至出9,並Μ醆酸乙醅萃取。以水清洗該 經收集之有櫬相,並於硫酸納之上乾堍。於興空中去除溶 _,並Κ些許冷甲酵播拌,獲得3.2s之榑題化合物, n . p . 1 9 6 - 1 9 8 1C ° ....................................................................................¥......................,ΤΓ....................^ (請先閲讀背面之注意事項再填寫本頁) 本紙張尺度遴用中鷗家樣準(CNS)甲4规格(210X297公藿) A6 B6 經濟部中夬樣準局貝工消费合作杜印裂 五、發明説明(8 ) ‘· 3 -羥甲某- 8- (2 -田氬羝腌某- fi -申笮某氩)-2 -甲基眯 皡「1. 1 Bf 啶 相似於買例2,由3S之3-甲鼸-8-(2-甲氧羰胺基-6-甲 笮基氧)-2-甲基咪唑[1,2-a]吡啶及400Bg之硼氫化納獲得 2.U之標題化合物,π.ρ, 185 — 187 C。 5. 8-(2 -珥氬羝防某-ft -田笮某防某1--二田某眯啤 Γ 1 . 9 - a 1 DH:睡 將4.5g之碘化納及6.63s之碳酸納加人至一種於40 0nl乾 嫌丙嗣中之4.038 8-胺基-2,3-二甲基咪唑[1,2-3]吡啶及 6.4U 2-甲氣羰胺基-6-甲笮基氬溶液中,於回流下,加 热該混合物6h。纆冷卻至室溫後,加入400 ml水,並於水 注真空中蒸除丙酮。然後,以每次200m 1_酸乙酯萃取該 殘留物水溶液三次。Μ 300Π1水清洗該經混合之有機萃取 液*於疏酸鎂之上乾然後濃縮。於氧化矽膠(甲笨: 二薷烷= 9:1為洗提液)上之層析分離法纯化該殘留物。 瀟縮Rf =0.2之部分,然後,自二異丙醚中再结晶。分離 出 4.7U (56»)之檷囲化合物,n.p. 136- 1381C。 a) 令溶解於丙酮中之此檷題化合物與12N之氫氯酸反應, 獲得此檷题化合物之氛化氫,m.P. 2 11 — 212¾ (dec)。 b) 令溶解於四氫呋喃中之此棟趙化合物與甲烷磺酸反應, 獲得此檷題化合物之甲烷磺酸鹽,m.p. 181-1821 (dec) Ο c) 令溶解於丙酮中之此檷纽化合物與反式丁烯二酸反懕, 裝......................訂.....................線 {請先閱讀背面之注意事項再填寫本頁} - 10 - 本紙張尺度遑用t _家標準(CNS)甲4规格(210X297公釐)"" 經濟部中夬標準局貝工消费合作社印«. A6 B6_ 五、發明説明(9 ) 獲得此襦題化合物之半反式丁烯二酸鹽,m.p. 191-192 V (dec) & 8-(?-田《»脐某-{^珥笮某氬1-2.3-二印某味皞 「1 . 2-a 1 af aft 於室漘下•將一種於150 nl乾嫌丙烯臃中之9.5s 2-甲氧 獷胺基-6-甲苄基氛溶液逐滴加入至一種於130b1乾嫌丙烯 臃中之7.288-羥基-2,3-二甲基畔唑[1,2-3]吡啶懸浮液 中•於此已先行加入於矽藻土 (例如Celite〉上之 8g商 業化氰化鉀(50X重量比)。將該混合物加熱至70 t · 9h.經冷卻至室溫後•將該混合物倒入至1公升之冰水中 ♦並以醋酸乙酯萃取三次。以蒸皤水清洗該經收集之有櫬 相,並於硫酸納之上乾埭。娌於真空中去除有櫬溶劑之後 ,《出該沉澱殘留物· Μ些許_酸乙酯及醚清洗,乾爍, 於異丙酵中再结晶之後,獲得2. 2s之檷S化合物,m. ρ. 176 - 177 Ό 〇 7. 8-(6 -甲某某笮某胺蓽)-2. 3-二甲某眯睞 n . υΐΗ:晾 於室溫下*將碘化納(15.0g)及碳酸納(31,0g)加入至一 種於丙酮(100*1)中之8-胺基-2,3-二甲基咪唑[1,2-a]吡 啶(14.7g)及6-甲基-2-硝基苄基氛(18.6g)溶液中•並於 回流下,加熱6h。於冷卻至室溫及蒸發溶劑後,令此殘留 物溶解於一種釀酸乙酷(200nl>及水(200ml)之混合物中· - 11 -本紙張尺度遑用t國圖家«準(CNS>T4/)t格(210X297公釐> <-—S.................................................................................装......................訂....................線 (請先閲讀背面之注意事項再填窝本頁} A6 B6 經濟部中夹櫟準局員工消费合作社印製 五、發明説明() 分離有機相。再M_酸乙酯(100®丨)萃取三次之後*令娌 琨合物之有櫬層於硫酸鎂之上乾嫌•並澹鏞至80ml之體稹 。12.1s之檷題化合物结晶成淡黄色固《。蒸發母液•並 K氧化矽膠(甲苯:二萼垸= 6:1為洗提液)上之層析分 離法鈍化該殘留物,而獲得額外之14g结晶物質。於自酷 酸乙酯中,將二部分再结晶之後·分離出21. 5g (76!«)之 標理化合物,·. Ρ. 160- 162*0。 a 8-(?.-笛=_丁氬甚嫌防某-6-甲笮基胺基)-2.3,二田甚 眯啤Π . 2 - a 1吡啶 此檷题化合物係根據實例1說明之步《製備,其係起始 自於丙酮(250ml)中之8-胺基-2,3-二甲基咪唑[1,2-a]吡 啶(4.8g>,2-第三丁氧基薄I胺基-6-甲苄基氛(9.2d·碘 化納(5.5g)及碳酸納(8.Og)。纯化係藉於氧化矽膠上(甲 苯/二雩烷= 20:1為洗提液)之層析分離法而進行,並自 二異丙醚中结晶而得7.1s (62X)之檷S化合物,m.p. 149 - 152t: ° a 只-(?-箪=丁氬某羝昉某-6-甲笮某氬)-2.3-二田甚眯 Kit Γ 1 . 9. - a 1W: ng 此檷鼷化合物係根據實例7說明之步驟製備•其係起始 自於丙鼷(35〇1«1)中之2,3-二甲基-8-羥基-咪唑[1,2-3]吡 啶(1.6g),2-第三丁氧基羰胺基-6-甲苄基》(3.1g),碘 化納(1. «g)及碳酸納(2.7g)。純化係箱於氧化矽膠上(甲 ................................................... .....................裝......................訂....................線 {請先閲讀背面之注意事項再填寫本頁) - 12 本纸張尺度遑用中家檫準(CNS)甲4规格(h〇><297公釐) 293008 經濟部t夹搮準局貝工消费合作杜印製 A6 B6 五、發明説明(11 ) 苯/二萼垸=5: 1為洗提液)之層析分離法而進行•並自 環己烷中结晶而得3.Os (78%)之禰醺化合物’ *.p. 128-1311: ° ia 抒_〇-箪三丁氬某薄防某-fi_田笮某昉某)_3_頃 _9_ 田蠤睐睥Μ . 2 - a 1 PH·.晾 此檷®化合物係根據實例7說明之步骤製備,其係起始 自於丙酮(250nl)中之8-胺基-3-甲醢-2-甲基咪唑 [1.2-a 1吡啶(4. Og),2·第三丁氣基羰胺基-6-甲笮基氯 (7.〇g),碘化納(4. U)及碳酸納(6. lg)。純化係藉於氧化 矽膠上(甲苯/二萼烷=9: 1為洗捉液)之曆析分離法而 進行,並自二異丙醚中结晶而得7.3g (8U)之禰題化合物 ,b . p . 2 1 0 - 2 1 2 C。 11 只-(2-箪芏丁氬某锥脓某- fi -田书某氪申牖-2-甲 某眯睞「1 . - a 1吡晾 a)於60t:,令4.77g之8-苄基氧-2-甲基咪唑[1,2-a] 吡啶於一種20ial之二甲基甲醮胺和2.3m丨磷醢f[之威斯梅 爾(Vils«eier>混合物中攪拌2.5h,然後·依平常之方式 加入冰/水和碳酸氫鉀。即可獲得8 -苄基氧-2 -甲基眯唑 [1,2-a]% 陡-3-後醒,b.p. 105 — 106Ό (自二異丙链) ,由此•根據Kaiiinski 等 J. Med. Che·. 876 (1985)之方法Η*將其去苄基化,則可獾得3-甲釀-8-羥 基-2-甲基咪唑[1,2-a]吡啶,in.p. 251 - 252 C。 { (.............................................................................................裝......................訂....................線 <請先閲讀背面之注意事項再填寫本頁一 _ 13 - 本纸張尺度遑用家檬準(CNS)<f4规格(210x297公复)—" 經濟部中央櫺準局貝工消费合作杜印製 A6 B6 五、發明説明(12 ) b)此禰题化合物係根據實例7說明之步驟製備•其係 起始自於丙緬(400ml)中之8 -理基-3 -甲釀-2-甲基味哩 [1,2-a]吡啶(2.4s),2-第三丁氧基羰胺基-6-甲苄基氯 (4.2g),醮化納(2.5g)及碳酸納(3.7g)。鈍化係藉於氧化 矽膠上(甲苯/二萼烷=9: 1為洗搌液)之層析分離法而 進行,並自二異丙醚酸乙酯中结晶而得4.4g (80S!)之 檷匾化合物,i«.p. 189-191C。 12.只-(?-防某-6-甲笮基胺基)-2.3-二甲某眯唑「1.2-31 吡唯 方法A : K 15 g之P d / C (5 X)觸媒處理一棰於甲酵(5 . 5 I >中之 8-(6-甲基-2-硝基苄基胺基)-2,3-二甲基咪唑[1,2-3]吡 啶(61g)溶液,並於RT,大氣壓力下,令其氫化1.5h。濾 除該觸媒·並將溶劑蒸發。令該殘留物溶解於沸騰之醋酸 乙酯(2.7 1)中。經冷卻至室溫後,分離出51g (82¾)之棵 題化合物,m.P. 206-2081C。 方法B : 於25-30=,將8-(2-第三丁氧基羰胺基-6-甲基苄基 胺基>-2,3-二甲基咪唑[1,2-a]吡啶(6.7g)分成數部分加 入至一種三氟醋酸(30b1)及苯甲醚(3ml)之混合物中。於 室溫下攪拌30分鏟之後*將該溶液加入至冰水ΠΟΟηΙ)中 ,然後,以6Η之氬氧化納溶液(75b丨)處理。濉出該沉澱物 ,並Μ氧化矽膠(甲苯/二萼烷=8: 1為洗提液)上之屬 .................................................................................裝......................訂.................…線 ~請先閱讀背面之注意事項再填窝本頁一 - 14 - 本紙張尺度遴用中蘭國家檫率(CNS)甲4现格(210X297公*) A6 B6 經濟部t夹揉準局Λ工消费合作杜印製 五、發明說明(15 ) 析分離法純化之。自醋酸乙酯中结晶之後,獲得3.Is (62*)之禰題化合物,通-p. 206 - 2081。 ia 8_-(2 -防甚-fi -田某笮某氬)-·? -甲静-9 -申某随1 Γ1.2-» 1 m ife 利用實例12(方法B)說明之步驟,起始自8-(2-第三 丁氧基羰胺基-6-甲基苄基氧)-3-甲釀-2-甲基邮唑 [1.2-a]吡啶(5.0g)及三氣醏酸(4〇ml),獲得3.57g (96¾)之檷題化合物,B.P. 144 - 150 C。 H. 8-(2 -7,氬某薄肱甚-fi -田某笮葚防其)-9.-3-二甲某眯 啤「1 . a 1 赃 PS 將溶解於二氣甲烷(10ml)中之氰甲酸乙酸(0.65g)逐 滴加人至一種於二氰甲烷(50·1)中之8-(2-胺基-6-甲基苄 基胺基)-2,3-二甲基咪唑[1,2-a]吡啶(0.98g)溶液中,並 於室溫下攪拌18h。然後,Μ飽和重碳酸纳水溶液(40 ·1) 萃取該溶液· Μ水(40·1)濟洗及蒸發。令該殘留物自Μ酸 乙酯/二異丙醚中再结晶析出。離析出〇.32g (26Χ)之櫟 β 化合物,h.p. 208 — 210C (dec)。 ia 8-(2-君T氬某禳粧某- fi-田甚笮某防某)-2.3-二田蠤 眯唑Μ . 2 - a 1 «:啶 此欏躧化合物係根據實例14說明之步驟製備,其係起 始自於二«甲烷(50·1)中之氯甲酸異丁酯(0.3g)及8-(2- - 15 - 本紙張尺度遑用+ 家樣準(CNS>甲4现格(210X297公釐> ia·先閱讀背面之注意事項再填寫本頁) 裝 -訂 線 g^30ii8 經濟部t央櫺準局Λ工消费合作社印襞 A6 B6_ 五、發明説明(14 ) 胺基-6-甲基苄基胺基)-2,3-二甲基咪唑[1,2-a]吡啶 (0.56g>。離析出 0.22g (29S!)之檷題化合物,b.p. 144- 146¾。 ia 8-(2 -里丙氬某羝肱某-fi -甲某苄某防某)-八二甲某 眯睐r m肝_晾 此檷》化合物係根據霣例14說明之步驟製備*其係起 始自於二氯甲烷(50»1)中之氯甲酸異丙酯(1.5g>及8-(2-胺基-6-甲基苄基胺基)-2.3-二甲基咪唑[1.2-a]吡啶 (0.98g)。離析出0.32g (25ϋί)之檷S化合物。 17. 8-(2 -箪二丁斑甚抽眩甚-R-珥某芊某防某)-.1-搏甲基 -2 -申某眯睐啶 此檷题化合物係根據實例2說明之步驟製備·其係起 始自於甲酵中之8-(2-第三丁氧羰胺基-6 -甲基苄基胺基 )-3 -甲醚-2-甲基咪唑[1,2-a]吡啶(〇.15g)及礓籯化納 (15ns),。離析出0· 12g之檷題化合物,H.P. 102 - 104Ό。 ia 8-(2-第三丁《某镅防蠤- fi-ff某笮某氬)-3-挥甲基_ -2-甲某眯睞啶 此禰题化合物係根據霣例2說明之步驟製備*其係起 始自於甲酵中之8-(2-第三丁氧羰胺基-6-甲基苄基氧)_ 3-甲醣-2-甲基眯唑[1,2-a]吡啶(0.20g)及硼氫化納 (19«^)〜離析出0.178之禰鼸化合物,1*1.140—,142:〇.。 .................................................................................^.......................玎..................... (請先閲讀背面之注意事項再填寫本頁一 - 16 - 本紙張尺度適Λ t ·函家掭承(CNS)f4现格(210X297公釐)— 五、發明説明(15 ) Α6 Β6 經濟部+夹樣準局貝工消费合作社印製 τ聿歷用 通式I之化合物及其鹽類具有價值之’此使其 可利用於工乘上。其特別顯現一種經發表之M酸分泌抑制 作用及對溫血動物之费及腸之極佳保_作用。於此親點’ 根據本發明之化合物可由多選揮性之作用’ 長期之作 用,優異之腾内效用C無明顯之副作用及廣泛之治療範園 等而區別。 ,’爾腸保謂作用,,偽表示避免及處理费腸失調*尤其偽 腸爾炎失調及》害(如胃潰瘍,十二指腰’爾炎*由 於酸過多或藥物引起之功能性罱病)•其起因可能係如微 機賴(例如幽門螺旋稈菌),妞菌毒素,藥物(例如某些 抗炎及抗風瀰劑),化學物(例如乙酵),胃酸或緊張吠 態。 於其優異之性霣中*經涠f定抗炎及抗分泌性霣之不同典 型,根據本發明之化合物令人訝異地證明其顯著儍於先前 技β習知之化合物。因為該些性霣•通式I之化合物及其 β蕖相容性鹽類顯然遘用為人類及動物蕖•其中,尤其利 用於處理和/或預防霣和/或腸之疾病。 因此,本發明進一步係Μ於利用根據本發明之化合物於 處理或預防上述提及之失序。 相似地,本發明包括利用根據本發明之化合物於製造處 理或預防上述提及之失序之Β藥。 本發明進一步包括使用根據本發明之化合物於處理或預 17 各紙張尺度遙用中鷗家*準(CKS>甲4洗格(210X297公釐) {請先閲讀背面之注意事項再填窝本頁) .裝 訂 線 五、發明説明(16 ) A6 B6 經濟部中央樣準局貝工消费合作社印製 防上文提及之失序。 本發明進一步係闢於含一或多種通式I之化合物和/或 其醫藥相容性類之《蕖。 該B蕖係鞴热練工作人員習知及热悉之方法製造。當做 B綦時,該根據本發明之B藥活性化合物(=活性物質) 可依此方式使用或較佳之方式係與通當之翳藥輔助物霣或 載體结合.形成錠劑,纆塗佈之錠劑,膠囊,栓劑,硬膏 _ (例如TTS) •乳爾,懸浮液或溶液之形式•其中,活 性物霣含量最好係於〇.1及95!«之間,且其中》由選擇逋當 之_助物質及載體,可搜得一種Β槩S方(亦即,一種維 持放鬆之配方或一棰腸配方),此正通於該活性物霣和/ 或逋於整體所須之效用。 > 由於热練工作人員之専業知識•所Μ其可瞭解逋用於所 須Β藥配方之輔肋物質及載體。除了溶劑*膠形成爾•栓 劑基底•錠劑輔助物質及其它活性物霣載體Μ外·亦可使 用如抗氧化劑,分敗劑,乳化劑.消泡劑,口味調整劑· 防腐劑•溶解繭,色素或特別係滲透促進劑及複合劑(例 如環糊精)。 腌用該活性物質可薄由口眼•腸霣外施藥或皮下施蕖。 一般言之,已證明施用該活性物質或口服施用物質之曰 用量約0.01至約20,較佳者0.05至5,最佳者0.1至 1.5mg/kg (基於艚簠),係有利於人類藥物之施用,其通 於Μ複式,最好係1至4次,個別施用,Μ達到所須之结果 。於腸S外處理之例中*可Μ相似之方法使用或(尤Μ皮 裝......................訂.........................線 <請先聞讀背面之注意事項再蜞窝本頁) - 18 - 本纸張尺度遴用中家揲準(CN8)T4规格(210X297公釐] A6 B6 嫌濟部中央搮準局Λ工消费合作社印裂 五、發明説明(17 ) 下施蕖該活性物霣而言)照規定較低之用簠。因為热練工 作人員之專業知識,其可易於設定每屆實例所須之活性物 質適當施用量及方式。 如果使用根據本發明之化合物和/或其邇類於處理上述 搌及之失調•該醫藥製備亦可含有一或多種取自其它族群 B蕖之B蕖活性组份,如制酸蕖,例如,氳氧化鋁•鋁酸 鎂;鎮定劑如苯並二氮雜卓類,例如戴哲潘(diazepan) ;解理藥如拜塔默威林(bietaraiverine) ’卡米落芬( ca»ylofU);抗副交感神經劑如氧酚赛落民( oxyphencyclimine) , 88 卡巴邁(phencarbamide);局 部麻醉藥如四卡因(tetracaine),普卡因(procaine) ;其它理宜者亦包括酵素•維生素或胺基酸。 此方面特別值得注意者係根據本發明之化合物與抑制酸 分泌作用之藥物之混合,該藥物如H2阻斷劑(例如西默太 丁(cUetidine),倫那太丁(ranitidine)) HViTATPase 抑制爾(例如歐默普卓(omeprazole),潘托普卓 (pantoprazole)) *或更甚者包括稱為末梢抗副交感神經 劑(例如派倫哲姘(Pirenzepine)*泰倫哲姘 (telenzepine))及霣酸對抗爾*其目地係為增強添加或 «添加覼念和/或消除或降低副作用為基礎之主要作用· 或更進一步與具有抗菌活性之物霣混合(例如頭孢菌素 (cephalosporins),四環素(tetracyclines) ·蔡陡酮酸 (nalidixic acid),盤尼西林(penicillins),或其它秘 鹽類),•以控制幽門蠼旋稈菌>。 <請先閲讀背面之注意事項再填寫本頁) 裝 .訂 .線 - 19 - 本紙張尺度遑用中家樣準(CNS)甲4规格(210X297公釐) A6 B6 五、發明説明(18 ) as珅果 由根據本發明之化合物所提供對於宵之優異保護作用及 胄酸分泌抑制作用,可由動物實驗棋型之研究而說明。已 提供數個將於其後詳细說明•於此撗型中所研究之根據本 發明之化合物•其係相當於該些霄例中,該些化合物之 目0 對於铒充滿之老鼠甭夕分泌拙制作用牖試 * % 表1所列係表示,由活體之經充滿五價贾酸之棋裝老鼠 胃之酸分泌作用,經十二指腸施藥後,根據本發明之化合 物之效果。
B_L
Ho. 用董 酸分泌抑制作用 (« m ο 1 / k g ) (% ) 5Γ ...............................裝......................訂.............-:…線 (請先閲讀背面之注意事項再填窝本頁} 經濟部t央標準局貝工消#合作社印製 2 6 100 4 10 100 5 3 100 6 3 100 - 20 本紙張足度遄用中家欉举(CNS)甲4蚬格(210X297公*) 8930U8 A6 B6 五、發明説明(19 ) 經濟部中央樣準局貝工消费合作社印製 方法 將經麻醉之老鼠(CD老鼠’母性’ 200-250g; 1.5g/U ί.a.氨基甲酸豳)進行氣管造口術,然後,由一種中間上 腹切開術將腹部開口 •並固定—條PVC辱管由口經食道’ 而另一條刖經由幽門•以此方式*導管末端正好伸人甭之 内腔。引導出幽門之導管經由於右腹部壁之横向開口而導 出外面。 該爾經完全刺激(約50-100ml)之後·連續通M37t:之 生理 NaCl 溶液(〇.5nl/min,出 6.8— 6.9; Brun-Unita I)。每間隔15分嫌收集此流出液(25nl]l苘),並進行 pH測定(出632.玻瑰竃極圧六417;直徑=5 mi», Metroh»),並Μ新配製之0.01N NaOH滴定該經分泌之 H C 1 至 pH 7 ( D 〇 s i m a t 6 5 5 M e t r 〇 h )。 溥酸分泌之横擬係於操作结束之後(亦即,於測定2個 初期部分之後),連鑛注人lug/kg( = 1.65al/h) i.v. 五價霣》t(左大賊靜K)約30分鐘。於連績注入五價甭酸 開始之後,以1 ml/kg 60分鐘之液«體積•纆十二指腸拖 用受澜試物霣。 Μ紅外埭照射及纆加熱之垫子(經由口眼溫度感懕器自 動無段控制),保持動物之體溫固定於37.8—38t:° 導致酸分泌作用之100Χ最大抑制作用係於表中指出。 <婧先閲讀背面之注意事項再蜞寫本頁} - 21 本紙張尺度遴用中鷗钃家樣準<CNS)甲4规格(210X297公*)
B505X 八Μ 1 化学式
RO
R1 R2 :HZ 'NHC0-R3
CHO
R1 (11)- R2
(III)
CHO
(VII) R2
(VIII)
Claims (1)
- R0NHCC-R3 第83100912號專利申請案 s Ο DO 中文申請專利範圍修正本(85年10月) C8 D8 六、申請專利範圍 公告本 1. 一種如下所示通示I之化合物 R1 (I) 其中 R0 表示甲基或羥甲基 R1 表示卜4C烷基 R2 表示1 -4C烷基 R3 表示卜4C烷氧基 A 表示0 (氣)或N Η 及其鹽類。 2. 根揀申謫專利範園第1項之通式I之化合物》其中R0代 表甲基。 3. 根揀申請專利範圍第1項之通式I之化合物,其中R0代 表羥甲基。 4. 根撺申請專利範圍第1項之通式I化合物,係選自包括 3-羥甲基-8-(2-甲氧羰胺基-6-甲苄基胺基)-2-甲基咪 啤[1 , 2 - a ]吡啶, 本纸張尺度適用中國國家標準(CNS ) A4規格(210x197公釐) ( 裝 ,1 {冰 (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 C8 DS 六、申請專利範圍 3-羥甲基- 8-(2-甲氧羰胺基-6-甲苄基氧)-2-甲基眯唑 〔1 , 2-a ] % 咱, 8-(2-甲氧羰胺基-6-甲苄基氧)-2,3-二甲基咪唑 [1,2-a]吡啶 8-(2-第三丁氧羰肢基-6-甲苄基胺基)-2,3-二甲基眯唑 [1 , 2-a]吡啶, 8-(2-第三丁氧羰胺基-6-甲苄基氧)-2,3-二甲基眯唑 [1,2-a]吡啶 8-(2-乙氧羰胺基-6-甲苄基胺基)-2,3-二甲基眯唑 [1 ,2-a]% 啶, 8-(2-異丁氧羰胺基-6-甲苄基胺基)-2,3-二甲基咪唑 [1,2 - a ]吡啶, 8-(2-異丙氧羰胺基-6-甲苄基胺基)-2,3-二甲基咪唑 [1,2-a]吡啶, · 8-(2-第三丁氧羰胺基-6-甲苄基胺基)-3-羥甲基-2-甲 基咪唑Π , 2-a]吡啶,及 8-(2-第三丁氧羰肢基-6-甲苄基氧)-3-羥甲基-2-甲基 眯唑[1,2-a]%啶•或其鹽類。 經濟部中央標準局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) 5. 根撺申請專利範圍第1項之通式I化合物,其係8-(2-甲氧羰胺基-6-甲苄基胺基)-2,3-二甲基咪唑[1,2-a]吡 啶或其_類。 6. —棰製備根據申請專利範圃第 1項之通式I化合物之方 法,包括 a) 為了製備通式I之化合物•其中R0代表羥甲基,令 通式I之化合物在惰性溶劑中·Μ適當之氫化物堪 本紙張尺度適用中國國家標準(CNS ) Α4規格(210 X 297公釐) A8 B8 C8 D8 經濟部中央標準局員工消費合作社印製 々、申請專利範圍 原, CHO其中R1*R2,R3及 A具有申請專利範圃第 1項之意 義*或包含 b) 為了製備通式I之化合物,其中R0代表甲基,令通 式B之化合物,其中R1及 A具有申請專利範圍第 1項之意義,與通 式IV之化合物反應, 本紙張尺度逋用中國國家標準(CNS ) Μ規格(210X297公釐) --------^裝------訂------^ (請先閲讀背面之注意事項再填寫本頁) A8 293008 ?8 D8 六、申請專利範圍 R2其中R2及R3具有申請專利範圍第 1項之意義,且X 代表一個適當之離去基,或包含 c ) 為了製備通式I之化合物,其中R0代表甲基,令通 式V之化合物,經濟部中央標準局員工消費合作社印製 (請先閲讀背面之注意事項再填寫本頁) 其中R1及R2具有申謫專利範圍第1項之意義,與通 式VI之化合物反懕, R3 - CO - Y ( VI ) 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) A8 B8 C8 D8 六、申請專利範圍 其中R3具有申請專利範圍第1項之意義*且Y代 表一個適當之離去基* 且如果須要,通而將所得之化合物I轉換成其鹽 類,或包括,如果須要*接著自化合物I之所得 鹽類釋放出化合物I。 7. —棰用於預防及治療腸宵失調之酱藥姐合物,其含有 根據申請專利範圍第1項之化合物和/或其一種B蕖 相容性鹽類。 a 根據申請專利範圍第1項之化合物及其«蕖相容性豔 類,其係用於預防及治療腸甭失調。 a 根揮申請專利範圍第1項之化合物,其係3 -羥甲基 -8- (2-甲氧羰胺基-6-甲苄基胺基)-2-甲基咪唑 [1,2-a]吡啶或其鹽類。 (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 本紙張尺度逋用中國國家標準(CNS ) A4規格(210X297公釐)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH45393 | 1993-02-15 | ||
| CH194593 | 1993-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW293008B true TW293008B (zh) | 1996-12-11 |
Family
ID=25684624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW083100912A TW293008B (zh) | 1993-02-15 | 1994-02-03 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US5665730A (zh) |
| EP (1) | EP0683780B1 (zh) |
| JP (1) | JP3447292B2 (zh) |
| KR (1) | KR100297057B1 (zh) |
| CN (1) | CN1052005C (zh) |
| AT (1) | ATE192151T1 (zh) |
| AU (1) | AU678434B2 (zh) |
| BG (1) | BG62773B1 (zh) |
| CA (1) | CA2156078C (zh) |
| CZ (1) | CZ287313B6 (zh) |
| DE (1) | DE59409312D1 (zh) |
| DK (1) | DK0683780T3 (zh) |
| ES (1) | ES2148317T3 (zh) |
| FI (1) | FI109537B (zh) |
| GR (1) | GR3033846T3 (zh) |
| HU (1) | HU219395B (zh) |
| IL (1) | IL108520A (zh) |
| MY (1) | MY111201A (zh) |
| NO (1) | NO304889B1 (zh) |
| NZ (1) | NZ261579A (zh) |
| PL (1) | PL175932B1 (zh) |
| PT (1) | PT683780E (zh) |
| RO (1) | RO117917B1 (zh) |
| RU (1) | RU2136682C1 (zh) |
| SG (1) | SG55184A1 (zh) |
| SK (1) | SK280822B6 (zh) |
| TW (1) | TW293008B (zh) |
| UA (1) | UA43841C2 (zh) |
| WO (1) | WO1994018199A1 (zh) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0767790B1 (en) * | 1994-06-20 | 2001-12-12 | Takeda Chemical Industries, Ltd. | Condensed imidazole compounds, their production and use |
| EP0773944A1 (de) * | 1994-07-28 | 1997-05-21 | Byk Gulden Lomberg Chemische Fabrik GmbH | Benzylimidazopyridine |
| CA2196078A1 (en) * | 1994-07-28 | 1996-02-08 | Gerhard Grundler | Imidazopyridine-azolidinones |
| AU3343295A (en) * | 1994-08-12 | 1996-03-07 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Imidazopyridine salt |
| US6132768A (en) * | 1995-07-05 | 2000-10-17 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors |
| JP2949474B2 (ja) * | 1995-08-28 | 1999-09-13 | 隆久 古田 | ペプシノーゲンi/ii比の変化率を基礎としたヘリコバクター・ピロリ除菌判定方法 |
| AU1545297A (en) * | 1996-01-26 | 1997-08-20 | Byk Gulden | Imidazopyridine halides |
| WO1997027192A1 (de) * | 1996-01-26 | 1997-07-31 | Byk Gulden Lomberg Chemische Fabrik Gmbh | 3-methylimidazopyridine |
| DE19602855A1 (de) * | 1996-01-26 | 1997-07-31 | Byk Gulden Lomberg Chem Fab | Neue 3-Methylimidazopyridine |
| WO1998042707A1 (en) * | 1997-03-24 | 1998-10-01 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Tetrahydropyrido compounds |
| ES2219890T3 (es) * | 1997-03-24 | 2004-12-01 | Altana Pharma Ag | Compuestos tetrahidropirido. |
| SE9802794D0 (sv) * | 1998-08-21 | 1998-08-21 | Astra Ab | New compounds |
| US6852739B1 (en) * | 1999-02-26 | 2005-02-08 | Nitromed Inc. | Methods using proton pump inhibitors and nitric oxide donors |
| EP1173439B1 (en) | 1999-04-17 | 2003-05-21 | ALTANA Pharma AG | Haloalkoxy imidazonaphthyridines |
| US6268385B1 (en) | 1999-08-26 | 2001-07-31 | Robert R. Whittle | Dry blend pharmaceutical formulations |
| US6312712B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Method of improving bioavailability |
| US6326384B1 (en) | 1999-08-26 | 2001-12-04 | Robert R. Whittle | Dry blend pharmaceutical unit dosage form |
| US6780880B1 (en) | 1999-08-26 | 2004-08-24 | Robert R. Whittle | FT-Raman spectroscopic measurement |
| US6262085B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| US6262086B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Pharmaceutical unit dosage form |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| US6316020B1 (en) | 1999-08-26 | 2001-11-13 | Robert R. Whittle | Pharmaceutical formulations |
| US6312723B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Pharmaceutical unit dosage form |
| DE10019714A1 (de) * | 2000-04-20 | 2002-01-10 | Gruenenthal Gmbh | Salze von bicyclischen, N-acylierten Imidazo-3-aminen und Imidazo-5-aminen |
| SE0003186D0 (sv) * | 2000-09-07 | 2000-09-07 | Astrazeneca Ab | New process |
| UA80393C2 (uk) * | 2000-12-07 | 2007-09-25 | Алтана Фарма Аг | Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці |
| SE0102808D0 (sv) * | 2001-08-22 | 2001-08-22 | Astrazeneca Ab | New compounds |
| DE10145457A1 (de) | 2001-09-14 | 2003-04-03 | Basf Ag | Substituierte Imidazo[1,2-a]-5,6,7,8-tetrahydropyridin-8-one, Verfahren zu ihrer Herstellung, sowie deren Verwendung zur Herstellung von Imidazo[1,2,-a]pyridinen |
| MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
| AU2003254282A1 (en) * | 2002-08-01 | 2004-02-23 | Nitromed, Inc. | Nitrosated proton pump inhibitors, compositions and methods of use |
| AR043063A1 (es) * | 2002-12-13 | 2005-07-13 | Altana Pharma Ag | Bencimidazoles 6-sustituidos y su uso como inhibidores de secreciones gastricas |
| HRP20050399B1 (hr) | 2003-03-10 | 2013-09-30 | Takeda Gmbh | Novi postupci za dobivanje roflumilasta |
| RU2241710C1 (ru) * | 2003-04-24 | 2004-12-10 | Ярославский государственный технический университет | Способ получения замещенных пиридо[1,2-а][1,3]бензимидазолов |
| US20080280944A1 (en) | 2003-11-03 | 2008-11-13 | Paula Fernstrom | Imidazo[1,2-A]Pyridine Derivatives For The Treatment Of Silent Gastro-Esophageal Reflux |
| AR049168A1 (es) * | 2004-05-18 | 2006-07-05 | Altana Pharma Ag | Derivados de benzimidazol |
| US8663694B2 (en) * | 2005-03-16 | 2014-03-04 | Takeda Gmbh | Taste masked dosage form containing roflumilast |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA81219B (en) * | 1980-01-23 | 1982-01-27 | Schering Corp | Imidazo (1,2-a) pyridines ,process for their preparation and pharmaceutical compositions containing them |
| WO1986003720A1 (fr) * | 1984-12-14 | 1986-07-03 | Moebius Ulrich | Fixation pour skis |
| EP0228006A1 (en) * | 1985-12-16 | 1987-07-08 | Fujisawa Pharmaceutical Co., Ltd. | Imidazopyridine compounds and processes for preparation thereof |
| US4831041A (en) * | 1986-11-26 | 1989-05-16 | Fujisawa Pharmaceutical Co., Ltd. | Imidazopyridine compounds and processes for preparation thereof |
| GB8722488D0 (en) * | 1987-09-24 | 1987-10-28 | Fujisawa Pharmaceutical Co | Imidazopyridine compound |
-
1994
- 1994-02-02 IL IL108520A patent/IL108520A/xx not_active IP Right Cessation
- 1994-02-03 TW TW083100912A patent/TW293008B/zh active
- 1994-02-07 RU RU95118439A patent/RU2136682C1/ru not_active IP Right Cessation
- 1994-02-07 KR KR1019950703389A patent/KR100297057B1/ko not_active Expired - Fee Related
- 1994-02-07 WO PCT/EP1994/000335 patent/WO1994018199A1/de not_active Ceased
- 1994-02-07 ES ES94906909T patent/ES2148317T3/es not_active Expired - Lifetime
- 1994-02-07 AT AT94906909T patent/ATE192151T1/de not_active IP Right Cessation
- 1994-02-07 DE DE59409312T patent/DE59409312D1/de not_active Expired - Fee Related
- 1994-02-07 HU HU9502386A patent/HU219395B/hu not_active IP Right Cessation
- 1994-02-07 CA CA002156078A patent/CA2156078C/en not_active Expired - Fee Related
- 1994-02-07 CN CN94191603A patent/CN1052005C/zh not_active Expired - Fee Related
- 1994-02-07 SG SG1996009096A patent/SG55184A1/en unknown
- 1994-02-07 PL PL94310171A patent/PL175932B1/pl not_active IP Right Cessation
- 1994-02-07 RO RO95-01468A patent/RO117917B1/ro unknown
- 1994-02-07 CZ CZ19952088A patent/CZ287313B6/cs not_active IP Right Cessation
- 1994-02-07 AU AU60391/94A patent/AU678434B2/en not_active Ceased
- 1994-02-07 JP JP51764594A patent/JP3447292B2/ja not_active Expired - Fee Related
- 1994-02-07 SK SK997-95A patent/SK280822B6/sk unknown
- 1994-02-07 US US08/505,271 patent/US5665730A/en not_active Expired - Fee Related
- 1994-02-07 DK DK94906909T patent/DK0683780T3/da active
- 1994-02-07 EP EP94906909A patent/EP0683780B1/de not_active Expired - Lifetime
- 1994-02-07 PT PT94906909T patent/PT683780E/pt unknown
- 1994-02-07 NZ NZ261579A patent/NZ261579A/en unknown
- 1994-02-08 MY MYPI94000281A patent/MY111201A/en unknown
- 1994-07-02 UA UA95083786A patent/UA43841C2/uk unknown
-
1995
- 1995-08-09 BG BG99855A patent/BG62773B1/bg unknown
- 1995-08-14 NO NO953187A patent/NO304889B1/no unknown
- 1995-08-14 FI FI953838A patent/FI109537B/fi not_active IP Right Cessation
-
2000
- 2000-06-30 GR GR20000401547T patent/GR3033846T3/el not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW293008B (zh) | ||
| TW593313B (en) | Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods | |
| US9932349B2 (en) | 8-carboxamido-2,6-methano-3-benzazocines | |
| TW301655B (zh) | ||
| TW199156B (zh) | ||
| TW203051B (zh) | ||
| CA2173876C (en) | Alkoxy alkyl carbamates from imidazo(1,2-a)pyridines | |
| TW200400186A (en) | (S)-4-Amino-5-chloro-2-methoxy-N-[1-[1-[2-tetrahydrofuryl-carbonyl]-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof , pharmaceutical composition containing the same , and intermediate therefor | |
| JPWO1995003308A1 (ja) | モルヒナン誘導体および医薬用途 | |
| JP2001510441A (ja) | ホスホジエステラーゼ4阻害剤としてのジアゼピノインドール | |
| AU2003235259A1 (en) | Benzimidazole derivatives | |
| TW210341B (zh) | ||
| CA2991572A1 (en) | 6-amino-quinoline-3-carbonitrils as cot modulators | |
| KR910006986B1 (ko) | 치환된 5,11-디하이드로-6H-디벤즈[b,e]아제핀-6-온의 제조방법 | |
| US20110009379A1 (en) | Indolinone compound | |
| TW219329B (zh) | ||
| TW438800B (en) | N-(2-benzothiazolyl)-1-piperidineethanamine derivatives, their preparation and their use in therapy | |
| CN112759544B (zh) | 3-(二甲氨基甲基)哌啶-4-醇衍生物制备方法和药物用途 | |
| TW200922943A (en) | Compounds | |
| JPH01110626A (ja) | ナフチリジン抗嫌気菌用化合物 | |
| RU2141958C1 (ru) | Производные 6-метокси-1н-бензотриазол-5-карбоксамида, способ их получения и содержащая их фармацевтическая композиция | |
| CN112759587A (zh) | 3-(二甲氨基甲基)哌啶-4-醇类衍生物及其制备方法和药物用途 | |
| US5356903A (en) | 1-cyclopropyl-4-pyridyl-quinolines | |
| TW553945B (en) | Triazolopurine derivatives, medicinal composition containing the derivatives, adenosine A3 receptor compatibilizing agent, and asthmatic remedy | |
| TW206230B (zh) |